Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Intranasal LMN-301 in Healthy Volunteers
NCT06030414Phase 1Completed
- Sponsor
- Lumen Bioscience
- Start
- Oct 2023
- Primary completion
- Dec 2023
- Modality
- Fc Fusion Proteins, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of LMN-301 in coronavirus disease 2019 (COVID-19) (4 cohorts), sponsored by Lumen Bioscience. Primary endpoints: Number of Participants With Adverse Events, Number of Participants Discontinuing From the Study at 28 days and 8 more. Started Oct 2023; status: completed.
02
Drugs
LMN-301
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06030414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06030414.